retatrutide triple agonist obesity trial just delivered the first top-line Phase 3 results for a in — and the findings from TRIUMPH-4 are striking👇 Weight loss with retatrutide as

10 Molecular dynamics simulations including the GLP-1R

For related setmelanotide indications (Bardet-Biedl syndrome), Canadian health technology assessments published in 2023 estimated annual costs of approximately $294,000 per year for pediatric patients and $441,000 per year for adults at full dose

(2025, June 23)

By working with the team at Maryland Trim Clinic, patients receive the exact kind of evidence-based, compassionate care necessary for successful metabolic health management

While they can be a meaningful tool to achieve an initial weight loss goal maintaining results after discontinuing GLP-1 treatments often requires diet and lifestyle changes

The 4 mg weekly dose provides significant benefit for many, while some require 8 mg for maximum effect